Hugel America announced the Biologics License Application (BLA) for LetibotulinumtoxinA for injection to treat moderate-to-severe frown lines in adult patients has been accepted for review by the U.S. Food and Drug Administration (FDA). LetibotulinumtoxinA is currently available in 28 countries worldwide and has been the market leader for five consecutive years in South Korea. "The FDA's acceptance of our BLA is an important milestone for Hugel as it brings us one step closer to our goal of becoming a top aesthetics brand in the U.S. by delivering high-quality beauty solutions that are accessible and attainable," says James Hartman, president of Hugel America. "The groundwork has been done in the botulinum toxin category, but there's still plenty of opportunity for growth. We believe the market can continue to evolve and we look forward to participating in that evolution."
Related Articles
Alastin Receives Two New Patents
Cytrellis Recieves FDA Clearance for Ellacor
Galderma’s Restylane Celebrates 25 Years